Barclays Maintains Overweight on Progyny, Raises Price Target to $80
Barclays analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $72 to $80.
Return on Capital Employed Overview: Progyny
Pulled from Benzinga Pro data Progyny (NASDAQ:PGNY) showed a loss in earnings since Q1, totaling $11.66 million. Sales, on the other hand, increased by 5.34% to $128.65 million during Q2.
Barclays Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $64
Barclays analyst Sarah James initiates coverage on Progyny (NASDAQ:PGNY) with a Overweight rating and announces Price Target of $64.
Progyny’s Stock Is Getting Hammered On Mixed Q2 Earnings; Outlook Lagging Street Consensus
Progyny Inc (NASDAQ:PGNY) reported Q2 EPS of $0.19, a turnaround from EPS loss of $(0.01) a year ago, edging out…
SVB Leerink Maintains Outperform on Progyny, Lowers Price Target to $59
SVB Leerink analyst Stephanie Davis maintains Progyny (NASDAQ:PGNY) with a Outperform and lowers the price target from $64 to $59.
ZProgyny Q2 EPS $0.19 Beats $0.08 Estimate, Sales $128.65M Miss $129.31M Estimate
Progyny (NASDAQ:PGNY) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.08 by 137.5 percent. This is a 1050 percent increase over losses of $(0.02) per share from the same